Main characteristics of the landmark cohort (n = 807) at inclusion and landmark
| Variable . | Inclusion visit (n = 807) . | 6-mo landmark visit . | ||
|---|---|---|---|---|
| n or median . | % or IQR . | n or median . | % or IQR . | |
| Sex | ||||
| Male | 497 | 61.6% | ||
| Female | 310 | 38.4% | ||
| Age, y | 73 | 67-79 | ||
| WHO classification at diagnosis | ||||
| RA | 141 | 17.5% | ||
| RARS | 139 | 17.2% | ||
| RCMD | 309 | 38.3% | ||
| RCMD-RS | 51 | 6.3% | ||
| 5q− syndrome | 49 | 6.1% | ||
| RAEB-1 | 94 | 11.7% | ||
| RAEB-2 | 1 | 0.1% | ||
| MDS-U | 23 | 2.9% | ||
| IPSS-R cytogenetic risk (n = 730) | ||||
| Very good | 84 | 11.5% | ||
| Good | 543 | 74.4% | ||
| Intermediate | 89 | 12.1% | ||
| Poor/very poor | 14 | 2.00% | ||
| IPSS-R risk (available in 691 patients*) | ||||
| Very low | 180 | 26.0% | ||
| Low | 297 | 43.0% | ||
| Intermediate | 167 | 24.2% | ||
| High | 42 | 6.1% | ||
| Very high | 5 | 0.7% | ||
| Hb level, g/dL | 10.1 | 9-11.3 | ||
| RBC-TD | ||||
| No | 601 | 74.5% | 592 | 73.4% |
| Yes | 206 | 25.5% | 215 | 26.6% |
| Platelets, ×109/L | 181 | 102-277 | 169 | 93-263 |
| Neutrophils, ×109/L | 2.4 | 1.4-3.9 | 2.3 | 1.4-3.7 |
| Treatment before visit | ||||
| ESA with or without G-CSF | 115 | 14.2% | 277 | 34.3% |
| G-CSF alone | 2 | 0.3% | 4 | 0.5% |
| HMA | 1 | 0.1% | 16 | 2.0% |
| HY | 0 | 0% | 3 | 0.4% |
| LEN | 3 | 0.4% | 22 | 2.7% |
| None | 686 | 85% | 485 | 60.1% |
| Time from diagnosis to inclusion, d | 37 | 19-61 | ||
| Time from inclusion to landmark, mo | 6.1 | 5.7-6.4 | ||
| Follow-up from landmark, mo | 37.8 | 17.0-58.8 | ||
| Variable . | Inclusion visit (n = 807) . | 6-mo landmark visit . | ||
|---|---|---|---|---|
| n or median . | % or IQR . | n or median . | % or IQR . | |
| Sex | ||||
| Male | 497 | 61.6% | ||
| Female | 310 | 38.4% | ||
| Age, y | 73 | 67-79 | ||
| WHO classification at diagnosis | ||||
| RA | 141 | 17.5% | ||
| RARS | 139 | 17.2% | ||
| RCMD | 309 | 38.3% | ||
| RCMD-RS | 51 | 6.3% | ||
| 5q− syndrome | 49 | 6.1% | ||
| RAEB-1 | 94 | 11.7% | ||
| RAEB-2 | 1 | 0.1% | ||
| MDS-U | 23 | 2.9% | ||
| IPSS-R cytogenetic risk (n = 730) | ||||
| Very good | 84 | 11.5% | ||
| Good | 543 | 74.4% | ||
| Intermediate | 89 | 12.1% | ||
| Poor/very poor | 14 | 2.00% | ||
| IPSS-R risk (available in 691 patients*) | ||||
| Very low | 180 | 26.0% | ||
| Low | 297 | 43.0% | ||
| Intermediate | 167 | 24.2% | ||
| High | 42 | 6.1% | ||
| Very high | 5 | 0.7% | ||
| Hb level, g/dL | 10.1 | 9-11.3 | ||
| RBC-TD | ||||
| No | 601 | 74.5% | 592 | 73.4% |
| Yes | 206 | 25.5% | 215 | 26.6% |
| Platelets, ×109/L | 181 | 102-277 | 169 | 93-263 |
| Neutrophils, ×109/L | 2.4 | 1.4-3.9 | 2.3 | 1.4-3.7 |
| Treatment before visit | ||||
| ESA with or without G-CSF | 115 | 14.2% | 277 | 34.3% |
| G-CSF alone | 2 | 0.3% | 4 | 0.5% |
| HMA | 1 | 0.1% | 16 | 2.0% |
| HY | 0 | 0% | 3 | 0.4% |
| LEN | 3 | 0.4% | 22 | 2.7% |
| None | 686 | 85% | 485 | 60.1% |
| Time from diagnosis to inclusion, d | 37 | 19-61 | ||
| Time from inclusion to landmark, mo | 6.1 | 5.7-6.4 | ||
| Follow-up from landmark, mo | 37.8 | 17.0-58.8 | ||
G-CSF, granulocyte colony-stimulating factor; MDS-U, MDS unclassified; RA, refractory anemia; RAEB, refractory anemia with excess of blasts; RARS, refractory anemia with ringed sideroblasts; RCMD, refractory cytopenia with multilineage dysplasia; RCMD-RD, refractory cytopenia with multilineage dysplasia and ringed sideroblasts.
Detailed cytogenetics missing in 77 patients; detailed BM blasts (total <5%) missing in 39 patients.